Topic: In conversation with
Darren Kelly, Ph.D., CEO of fibrosis-focused companies Certa Therapeutics and OccuRx, discusses his many jobs and the need for few fibrosis drugs.
Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
Former Ciox CEO Paul Roma has been installed as general manager of IBM's Watson Health unit with plans to refocus the project’s efforts.
Cydan co-founders, CEO Chris Adams and R&D chief James McArthur discuss their hunt for orphan drugs.
Raj Krishnan discusses building Biological Dynamics, isolation methods for diagnostic testing and more.
Halozyme CEO Helen Torley discusses the company’s two-pronged strategy, what’s up next for the company and why biotechs are filing IPOs earlier.
Nine years later after Emil Kakkis started Ultragenyx, he reflects on how he’s preserved the culture of a small biotech even as it expands beyond 700.
ArunA Bio CEO Mark Sirgo and Chief Scientific Officer Steve Stice discuss exosomes and how they can be harnessed to treat CNS diseases.
Sabrina Johnson discusses her journey from a CNS-focused biotech to founding her own women's health company.
We caught up with Tony Johnson, CEO at Goldfinch Bio, and discussed why investment and development in kidney disease has lagged.